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Abstract
Merkel cell carcinoma (MCC) is a highly aggressive skin cancer with an increasing incidence. The understanding of the
molecular carcinogenesis of MCC is limited. Here, we scrutinized the PI3K/AKT pathway, one of the major pathways
activated in human cancer, in MCC. Immunohistochemical analysis of 41 tumor tissues and 9 MCC cell lines revealed high
levels of AKT phosphorylation at threonine 308 in 88% of samples. Notably, the AKT phosphorylation was not correlated
with the presence or absence of the Merkel cell polyoma virus (MCV). Accordingly, knock-down of the large and small T
antigen by shRNA in MCV positive MCC cells did not affect phosphorylation of AKT. We also analyzed 46 MCC samples for
activating PIK3CA and AKT1 mutations. Oncogenic PIK3CA mutations were found in 2/46 (4%) MCCs whereas mutations in
exon 4 of AKT1 were absent. MCC cell lines demonstrated a high sensitivity towards the PI3K inhibitor LY-294002. This
finding together with our observation that the PI3K/AKT pathway is activated in the majority of human MCCs identifies
PI3K/AKT as a potential new therapeutic target for MCC patients.
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Introduction
Merkel cell carcinoma (MCC) is a very aggressive malignant
skin tumor. The disease typically affects elderly patients. It is
preferentially localized in the chronically UV-exposed skin. The
correlation between UV light and MCC is probably due to the
immunosuppressive rather than the mutagenic effect of UV
irradiation. In patients with immunosuppression, MCC may occur
at a significantly younger age.
The pathogenesis of MCC is as yet not completely understood
[1], but the recent demonstration that the Merkel cell polyoma
virus (MCV) DNA is frequently present in MCC suggests a viral
induced carcinogenesis [2,3]. Despite the recent demonstration
that MCV infected MCC cells require expression of the MCV
encoded T antigens for proliferation and survival [4], little is
known on cooperating oncogenic events. Previous studies found no
evidence for mutations in classical oncogenes [5].
Still, high resolution comparative genomic hybridization
revealed a number of chromosomal regions with gains and losses
in MCC; the frequent loss of chromosome 10 where the tumor
suppressor gene phosphatase and tensin homologue (PTEN) is
encoded, suggests that aberrations of the PI3K/AKT pathway
may be involved in the pathogenesis of MCC [6]. Moreover, while
inactivating PTEN mutations are rare in MCC, the lack of PTEN
protein expression is frequent observed in MCC [7].
The PI3K/AKT (phosphatidylinositol 3-kinase/v-akt murine
thymoma viral oncogene homologue) pathway is a major signaling
pathway downstream of many growth factor receptors and
possibly the most frequently activated signaling pathway in human
cancer [8]. Indeed, it has an important impact on apoptosis,
proliferation, cell growth and malignant transformation. PI3K
contributes to the signaling from receptor tyrosine kinases upon
growth factor binding and generates the second messenger
phosphatidylinositol-3,4,5-trisphosphate (PIP3). PTEN reverses
this step. PIP3 induces downstream phosphorylation and activa-
tion of the survival kinase AKT1. Besides loss of PTEN, the PI3K/
AKT pathway can be activated by oncogenic mutations. Somatic
mutations in the PIK3CA gene, encoding for the a isoform of the
p110 subunit of PI3K, have been identified in a wide variety of
human tumors including benign skin tumors [9,10]. Furthermore,
an oncogenic hotspot mutation in the pleckstrin homology domain
(PHD) of AKT1 is present in several tumor entities, albeit at a
lower frequency than PIK3CA mutations [11].
Here, we demonstrate PI3K/AKT pathway activation, which is
independent of the presence of MCV, and oncogenic PIK3CA
mutations in human MCC. Activating PIK3CA mutations appear
to occur at a low frequency, indicating that additional mechanisms
contribute to PI3K/AKT pathway activation in MCC.
Materials and Methods
Sample acquisition
Formalin-fixed paraffin embedded histologically proven MCC
samples (primary tumors and metastases) were retrieved from
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DNA isolation. Written, informed consent had been obtained from
all patients to use tumor material not needed for histopathological
diagnosis for further scientific workup; the study was per-
formed according to the guidelines of the local ethics committee
(Ethikkommission der Medizinischen Fakulta ¨t der Universita ¨t
Wu ¨rzburg; sequential study number 124/05) and the declaration
of Helsinki. In addition, MCC cell lines were used. The cell lines
WaGa, BroLi, HeRo and LoKe were derived from MCC patients
of the Department of Dermatology, University of Wu ¨rzburg [4],
while UISO, [12] MCC13, [13] MCC26 [14], MKL-1 and MKL-
2 [15] have been established in other laboratories. DNA was
isolated from cell lines and formalin-fixed paraffin-embedded
tissues containing at least 60–80% of tumor cells using standard
protocols.
Immunohistochemistry
Immunohistochemistry was performed using a tissue micro-
array for MCC, malignant melanoma and basal cell carcinoma.
The staining followed standard protocols. The antibody was
directed against phosphorylated AKT at threonine 308 (rabbit
polyclonal (#38449), Abcam, Cambridge, UK) and was used at a
dilution of 1:200. The overall pAKT T308 staining intensity
(not the frequency of positive tumor cells) was scored from 0
(negative), 1+ (weak), 2+ (strong), and 3+ (very strong) by two
individual investigators (R.H. and J.C.B.). Each sample was
represented in triplicate on the tissue microarray. In total, 41
samples (most of them not identical with the MCC used for
genetic analyses; 14 primary tumors and 27 metastases) were
evaluated on the MCC tissue microarray, as well as 67
melanomas (17 nodular, 17 acrolentiginous, 16 lentigo maligna
melanoma, 17 melanoma metastases) and 45 basal cell carcino-
mas (20 nodular, 17 nodular and ulcerated, 2 nodular and
pigmented, 6 not available).
Knock down of the MCV LT antigen
The MCV positive MCC cell lines WaGa, BroLi, MKL-1 and
MKL-2 were infected with the lentiviral shRNA vector KH1
encoding either a scrambled shRNA or a shRNA targeting the
MCV T antigen mRNAs. Successful knock down of large and
small T antigen in MCV positive MCC cells using this construct
has been recently described [4]. Total cell lysates were harvested
on day 5 following infection and analyzed by immunoblotting. T
antigen knock down was confirmed using the Large T antigen (LT)
specific antibody CM2B4 [16]. a-AKT and a-phospho-AKT
(T308 and S473) antibodies were purchased from Cell Signaling
(Danvers, MA, USA).
PI3K/AKT inhibition
Cells were seeded in 96 well plates and the PI3K inhibitor was
added at varying concentrations. After an incubation period of 24,
48 and 72 hours cellular metabolic activity was assessed by the
MTS assay (CellTiter 96H AQueous One Solution Cell Prolifer-
ation assay, Promega Corporation, Madison, WI, USA). To this
end, 10 ml of CellTiter 96H AQueous One Solution Reagent
containing a tetrazolium compound (MTS) were added to each
well and the cells were incubated for approximately 5 hours at
37uC. Metabolically active, viable cells convert MTS into a
colored formazan product that was measured in a spectrophoto-
metric microplate reader (Perkin-Elmer Inc., MA, USA) at
493 nm. Furthermore, the cellular DNA content was measured
in ethanol fixed, propidium iodide stained cells by flow cytometry
as described previously [4].
Genetic analyses
Exons 9 and 20 of the PIK3CA gene were sequenced directly.
These exons contain the majority of PIK3CA mutations yet found
in human cancer. Samples which could not be sequenced
successfully were analyzed by a recently described, more sensitive
PIK3CA SNaPshotH assay in combination with a nested-PCR
approach [17]. This assay covers the most important hotspot
mutations at codons 542, 545 and 1047 of the PIK3CA gene.
Furthermore, exon 4 of AKT1 was sequenced directly, as this exon
harbors the E17K hotspot mutation. In 8 MCC cell lines, exon 3
of AKT3 was sequenced directly. Primer sequences and PCR
conditions can be obtained from the authors. The presence of
MCV DNA was assessed as described previously [2].
Statistical analysis
After the data passed the Shapiro-Wilk normality test, statistical
differences between two groups were evaluated by the t-test, and
between more than two groups by the repeated measures ANOVA
followed by the Dunnett’s multiple post test. A p value#0.05 was
considered as significant.
Results
AKT activation in MCC
To investigate a possible activation of the PI3K/AKT pathway in
MCC, immunohistochemical staining was performed for phospho-
AKT threonine 308 (pAKT T308) taking advantage of a MCC tissue
microarray. In total, 41 MCC samples (14 primary tumors and 27
metastases from a total of 26 patients) were evaluated. Expression of
pAKT T308 was scored from 0 (negative) to 3+ (strongly positive).
Figure 1. Activating phosphorylation of the AKT protein at
position threonine 308 in Merkel cell carcinoma, malignant
melanoma and basal cell carcinoma. T h ep r e s e n c eo fA K T
phosphorylated at T308 was analyzed by immunohistochemistry using
a phospho-specific antibody on tissue micro arrays representing 41
MCCs (each in triplicates), 45 basal cell carcinomas (BCC) and 67
melanomas, respectively. Samples were scored from 0 (negative) to 3+
(strongly positive). The percentage of the samples for each expression
score is indicated as bar graph and examples for the staining intensity
in MCC are depicted below. In total, 88% of MCC samples showed
strong (+2) or very strong (+3) staining for phospho-AKT T308, while
59% of melanoma samples were observed in these categories. Basal cell
carcinoma showed only negative or weak AKT phosphorylation.
doi:10.1371/journal.pone.0031255.g001
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PIK3CA AKT1 IHC
no. sex age type MCV Exon 9 Exon 20 Exon 4
pAKT
T308
1 f 46 cell line (UISO) 2 wt wt* wt 2
2 f 80 cell line (MCC13) 2 wt wt wt 2
3 m 64 cell line (MCC26) 2 wt wt wt 2
4 m 26 cell line (MKL-1) + wt wt wt 3
5 m 55 cell line (BroLi) + wt wt wt 3
6 m 67 cell line (WaGa) + wt wt wt 2
7 f 73 cell line (HeRo) + wt wt wt 3
8 m 64 cell line (LoKe) + wt wt wt 3
9 m 83 metastasis + wt* 22 2
10 2 70 metastasis 2 wt* 22 2
11 2 44 metastasis + wt wt 22
12 2 77 metastasis + wt* 22 2
13 2 45 metastasis + wt wt wt 2
14 f 80 metastasis + wt wt wt 2
15 m 66 metastasis + wt* 22 2
16 m 68 metastasis + wt* 22 3
17 m 2 metastasis 2 wt* wt* 22
18 f 77 metastasis + wt* wt* 2 2
19 f 72 metastasis + wt* wt* 2 2
20 f 56 metastasis + wt* wt* 22
21 f 68 primary tumor + wt wt* wt 2
22 m 46 metastasis 2 wt wt* wt 2
23 m 83 metastasis + E545Q wt wt 3
24 m 64 metastasis + wt wt* wt 2
25 m 77 metastasis + wt wt 2 2
26 m 75 primary tumor + E542K wt wt 2
27 m 75 metastasis + wt* wt* 22
28 m 79 primary tumor + wt* 22 2
29 2 58 metastasis + wt wt* 22
30 2 73 metastasis 2 wt* wt* wt 2
31 f 80 metastasis + wt* wt* 22
32 m 93 primary tumor 2 wt* wt* 22
33 m 77 primary tumor + wt* 2 wt 2
34 f 65 primary tumor + wt wt wt 2
35 f 72 metastasis + wt* wt* 22
36 m 82 primary tumor + wt wt* wt 2
37 m 80 primary tumor + wt* wt* 22
38 f 89 primary tumor + wt wt wt 2
39 m 62 metastasis + wt wt* wt 2
40 m 55 primary tumor + wt wt wt 2
41 f 93 primary tumor + wt wt 22
42 m 88 metastasis + wt wt* 22
43 m 84 primary tumor + wt* wt* 22
44 m 53 primary tumor + wt wt* 22
45 m 49 primary tumor + wt* wt* 22
46 m 82 metastasis + wt* wt* wt 2
Age, age at thetime of diagnosis;m,male; f, female;MCV, Merkel cell polyoma virus (the MCVstatuswasassessed asdescribed previously [2]); wt, wild-type; wt*, these samples
c o u l dn o tb es e q u e n c e dd i r e c t l y ,b u tw e r ea n a l y z e db yam o d i f i e dS N a P s h o t H assay; 2, not available; IHC pAKT T308, immunohistochemistry for phospho-AKT threonine 308
scored from 0 (negative) to 3+ (very strong) staining intensity; it has to be noted that only 9 samples used for mutation analysis were also present on the tissue microarray.
doi:10.1371/journal.pone.0031255.t001
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23 (56%) as strong (2+) and 13 (32%) as very strong (3+)f o r
their respective pAKT T308 expression (Figure 1). There were no
significant differences between primary tumors and metastases
regarding pAKT expression (mean expression scores of 2.36 (primary
tumors) and 2.07 (metastases); p=0.23). In addition, 8 MCC cell lines
were stained for pAKT T308 (Table 1). Four cell lines revealed a
strong (2+) and four MCC cell lines a very strong (3+) expression of
pAKT T308. The immunohistochemical results obtained by
analyzing both MCC tumor tissue and cell lines indicate that in the
majority of MCC the PI3K/AKT pathway is activated.
To compare the level of AKT activation in MCC with other
skin cancers, we additionally performed immunohistochemical
staining for pAKT T308 in 67 malignant melanomas, a tumor
with established frequent AKT pathway activation [18,19], and 45
basal cell carcinomas which have been shown to be characterized
by only low levels of phospho-AKT [20,21]. In line with these pre-
published data, basal cell carcinomas stained negative or very
weakly for pAKT, while melanomas revealed a higher phosphor-
ylation (Figure 1). Malignant melanoma showed lower levels of
AKT phosphorylation than MCC with 59% of samples catego-
rized as strong (+2) or very strong (+3), compared with 88% of
MCC samples. However, the comparability of the different tumor
entities might be diminished by different proportions of primary
versus metastatic tissues.
AKT activation is independent of MCV
Given the recent discovery that most MCCs are characterized
by the integration of a polyoma virus, i.e. the Merkel cell
polyomavirus (MCV), it is important to note that the oncogenic
proteins encoded by polyomaviruses have been implicated in the
activation of the PI3K/AKT pathway. For example, SV40 small
Figure 2. Merkel cell polyomavirus T antigens do not affect AKT phosphorylation in Merkel cell carcinoma. a) Total cell lysates of 7
MCV positive and 3 MCV negative MCC cell lines were subjected to Western blot analysis applying antibodies to pAKT
T308, pAKT
S473 and tubulin.
Signal intensity was quantified using the imageJ software and the values normalized p-values according to the Mann-Whitney are indicated. b) The
indicated cell lines were infected with the lentiviral shRNA vector KH1 encoding GFP and either a shRNA targeting all MCV TA mRNAs or a scrambled
shRNA; Infection rates as determined by GFP flow cytometry analysis were 98% for WaGa, 94% for BroLi, 90% for MKL-1 and 96% for MKL-2. Total cell
lysates harvested on day 5 following infection were then analyzed by immunoblotting for expression of large T antigen (LTA) and AKT and for the
presence of AKT phosphorylated at T308 or S473. The variations in molecular size of the LTA proteins in the different cell lines are due to different
stop codon mutations truncating the C-terminal part of the protein. c) Treatment with the PI-3 kinase inhibitor LY-294002 demonstrated inhibition of
AKT phosphorylation at the phosphorylation sites T308 and S473 by blocking the upstream kinase.
doi:10.1371/journal.pone.0031255.g002
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dephosphorylates AKT on both activating phosphorylation sites
[22]. Consequently, we addressed the possible contribution of MCV
T antigens to AKT activation in MCC cells. To this end, AKT
phosphorylation was measured by Western blot analysis in seven
MCV positive and three MCV negative cell lines. Quantification
of the western blot signals, however, demonstrated lack of any
significant correlation between pAKT and MCV status (Figure 2
a). Furthermore, a possible functional role of the MCV T antigens
on AKT activation in MCC was tested by silencing T antigen
expression in four MCV positive MCC cell lines by infection with a
lentiviralshRNA constructtargeting Large as wellas smallT antigen
(LT and sT) mRNA; LT and sT mRNA are derived by alternative
splicing from the same genomic locus and share common sequences
in exon 1 [3]. T antigen knock down did not affect phosphorylation
ofAKTatT308andS473inanyofthetested celllines(Figure 2 b).
In contrast, treatment with the PI-3 kinase inhibitor LY-294002
demonstrated that AKT phosphorylation at these two sides can be
inhibited by blocking the upstream kinase (Figure 2 c).
In accordance with the observations in the cell lines, the
expression level of pAKT T308 in situ did not correlate with the
MCV status (i.e. immunohistochemical mean scores of 2.11 and
2.21 for MCV negative (n=9) and positive (n=29) samples,
respectively; p=0.74). These lines of evidence strongly suggest that
the MCV T antigens are not critical for AKT pathway activation
in MCC cells, although it cannot be excluded that the difference
between MCV negative and positive samples would reach
significance with a higher number of samples.
PIK3CA mutations in MCC
In many cancers, PI3K/AKT pathway activation is mediated
by oncogenic mutations in PIK3CA and AKT1 genes. Thus, we
tested both the MCC tissue samples as well as the MCC cell lines
for PIK3CA and AKT1 hotspot mutations. The characteristics of
the patients and samples are given in Table 1. In total, 46 MCC
samples (14 primary tumors, 24 metastases and 8 cell lines) were
analyzed. Heterozygous PIK3CA mutations were identified in two
out of 46 samples (4%) (Figure 3). Both mutations (E542K and
E545Q) are localized in exon 9 of PIK3CA, which encodes the
helical domain, and in both cases the tumors harbored MCV
DNA. Both mutations were tested by an independent second PCR
and additionally by a modified PIK3CA SNaPshotH assay. The
detected mutations were independently confirmed by these
alternative methods. DNA isolated from peripheral blood
lymphocytes revealed a wildtype status in both cases, thus
confirming the somatic nature of the mutations. Subsequently,
additional samples of the two patients were tested. The patient
with the E542K mutation in the primary tumor revealed the same
mutation in two metastases of the temple and the parotid gland.
The E545Q mutation found in a metastasis of the second patient
was detected in two of three further metastases on the head. These
results suggest that in both cases the mutation occurred before
metastatic tumor spread.
The two MCC samples harboring a PIK3CA mutation were also
present on the tissue microarray. The sample with the E542K
mutation revealed a strong (2+) and the one with the E545Q
mutation a very strong (3+) pAKT T308 protein expression
(Table 1). Increased AKT phosphorylation can also be caused by
defined AKT mutations. The E17K AKT1 mutation causes a
pathological localization of AKT1 to the plasma membrane and
thereby stimulates downstream signaling proteins [23]. Sequenc-
ing of exon 4 of AKT1, containing the E17K hotspot locus, was
possible for 24 samples, but did not reveal any AKT1 mutation in
MCC. In addition, exon 3 of AKT3 harbouring the E17 hotspot
locus was sequenced in 8 MCC cell lines (UiSo, MCC13, MCC26,
MKL-1, LoKe, WaGa, HeRo, MaTi, BroLi), but did not reveal
any mutations.
MCC cells are sensitive to PI3K inhibition
We analyzed whether inhibition of the PI3K/AKT pathway
would impact the viability and growth of MCC cells. To this end,
we incubated 5 MCC cell lines (WaGa, MKI-1, MKI-2, MCC13,
UISO) for 24, 48 and 72 hours with the PI3K inhibitor LY-
294002 at different concentrations (range 12.5–50 mM) and
subsequently analyzed the cells using the MTS assay. In addition,
since inhibition of the AKT pathway is regarded as a reasonable
therapeutic option in melanoma [24,25], two melanoma cell lines
carrying known PI3K/AKT pathway activating mutations served
as positive controls; Skmel-28 was described to have a PTEN
mutation [26] while sequencing of the NRAS gene in BLM cells
revealed a Q61R mutation (data not shown). LY-294002 reduced
the metabolic activity for all 6 MCC cell lines in a time and dose
dependent manner between 10–95% (Figure 4). Indeed, at all
time points analyzed the means were significantly different
(p,0.0001; repeated measures ANOVA); Dunnett’s multiple post
test revealed significantly inhibition by each inhibitor concentra-
tion compared to control (p,0.05). Interestingly, the MCC cell
lines demonstrated in response to the PI3K inhibitor at least an
equal reduction in MTS signal as the melanoma cell lines, which
are proliferating much faster than most of the MCC cell lines
(Table 2). The MTS assay does not distinguish between apoptosis
and cell cycle arrest. Therefore, we performed DNA staining after
40 hours of LY-294002 (25 mM) treatment. Only WaGa cells
displayed a strong increase in sub-G1 cells at this time point while
all other cell lines - although dead cells were increased in all cases
in the presence of LY-294002 – showed only a moderate apoptotic
response (Table 2). Cell cycle arrest induced by the PI-3 kinase
Figure 3. PIK3CA hotspot mutations in Merkel cell carcinoma. (a)
The heterozygous p.E542K (c.G1624A) PIK3CA hotspot mutation was
detected in sample no. 27 by direct sequencing (left) and a PIK3CA
SNaPshotH assay (right) covering the most frequent hotspot PIK3CA
mutations. The number of the wildtype codons is indicated above the
peaks in the SNaPshotH assay. In brief, the SNaPshotH assay comprises a
multiplex PCR for exons 9 and 20 of PIK3CA, followed by extension of 4
primers specific for the most frequent PIK3CA hotspot mutation loci.
Because fluorescent dideoxynucleotides are used for this primer
extension step, only one peak appears at the base position with the
potential mutation. The color of the peak allows discrimination of
wildtype and mutated alleles. (b) The heterozygous p.E545Q (c.G1633C)
PIK3CA hotspot mutation was detected in sample no. 24 by direct
sequencing (left) and a PIK3CA SNaPshotH assay (right) covering the
most frequent hotspot PIK3CA mutations. The number of the respective
wildtype codon is indicated above the peaks in the SNaPshotH assay.
doi:10.1371/journal.pone.0031255.g003
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three different concentrations. After the indica t e dt i m ep e r i o dt h ec e l l sw e r es u b j e c t e dt ot h eM T Sa s s a yi nt r i p l i c a t e s .T h er e d u c t i o ni ne x t i n c t i o nr e l a t i v et ot h e
DMSO (solvent of LY-294002) controls is depicted. The graphs represent mean values (6 standard deviation) of at least three independent experiments.
doi:10.1371/journal.pone.0031255.g004
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decrease in S-phase cells was quite moderate in many cases
(Table 2). Although we know from previous experiments that a cell
cycle arrest is difficult to demonstrate in the slowly cycling MCC
cells [4] it is likely that not only reduced cell numbers but also
reduced metabolic activity per cell may contribute to the effects in
the MTS assay. Nevertheless, analysis of the cellular DNA content
suggests that both, cell cycle arrest as well as apoptosis induction
contribute to inhibition by LY294002 in MCC cells.
Discussion
PIK3CA mutations have been already identified in a broad
range of human cancers at varying frequencies, including liver
(36%), breast (26%), colon (25%), urothelial (13%), ovarian (9%),
gastric (7%), brain (6%), and lung cancer (2%) as well as leukaemia
(1%) [9,27]. The present study adds Merkel cell carcinoma to this
list of human cancers harboring PIK3CA mutations, although in
MCC these mutations occur obviously at a low frequency. Both
mutations are localized in the helical domain, whereas in most
other cancers, mutations in the kinase domain, i.e. in exon 20, are
more common (www.sanger.ac.uk/genetics/CGP/cosmic/). Nev-
ertheless, the E542K mutation is one of the most frequent PIK3CA
hotspot mutations and results in a strong activation of PI3K [28].
The E545Q missense mutation is less frequent but has been
described in breast, anaplastic thyroid, ovary, and esophageal
cancer [29].
To the best of our knowledge, this is the first report of oncogenic
mutations in human MCC. Notably, the analysis of several other
oncogenes including HRAS, KRAS, NRAS, BRAF, C-KIT, and genes
of the Wnt pathway did not show any mutations in human MCC
[5,30,31,32,33]. Indeed, all of the previously reported mutations in
MCC were restricted to tumor suppressor genes. PTEN mutations
were observed at a very low frequency, although loss of
heterozygosity at the PTEN locus at chromosome 10q seems to
be a frequent event [34]. Similarly, mutations in other tumor
suppressor genes such as p53, p73 and CDKN2A have been
reported, however, only in a very small fraction of MCCs.
Immunohistochemical analysis of the two MCC tumors
carrying activating PIK3CA mutations demonstrated a strong
AKT phosphorylation; this observation is in line with the fact that
these mutations contribute to an activation of the PI3K/AKT
signaling pathway. However, the two tumors harboring the
activating PIK3CA mutations were not exceptional with respect
to AKT pathway activity. In fact, 88% of a series of 41 MCC
tissues were classified in the same categories (strong or very strong
staining for pAKT T308) suggesting alternative mechanisms (e.g.,
PTEN alterations) of AKT pathway activation in the majority of
cases.
Merkel cell polyomavirus has been recently identified as a
widespread virus which upon integration into the genome of MCC
precursor cells and acquisition of truncating mutations in the viral
large T antigen is likely to contribute to MCC development and
progression [3,16,35]. In this respect we recently demonstrated
that MCV infected MCC cells require expression of the MCV T
antigens for proliferation and survival [4]. MCV genomes encode
for the presumably oncogenic large and small T antigens; for the
respective homologs encoded by SV40 it has been demonstrated
that they can activate the AKT pathway. While for small T this
happens via inhibition of the protein phosphatase 2A [22], large T
antigen activates the AKT pathway through its interaction with the
insulin receptor substrate 1 [36]. Surprisingly, however, shRNA
knock down of both MCV T antigens in infected MCC cell lines
did not affect AKT phosphorylation and the lack of correlation
between MCV status and AKT phosphorylation in the tumor
samples also suggests that the MCV viral T antigens do not
contribute to AKT pathway activation in MCC cells, although the
significance of the latter observation is impaired by the low
number of MCV negative samples. Thus, the presence of the viral
proteins seems neither to be sufficient nor necessary for AKT
pathway activation in MCC. A very recent report demonstrating
that transformation of rodent fibroblasts by MCV small T antigen
is independent of PP2A binding further supports that MCV T
antigens function different than the related SV40 oncoproteins
and that the AKT pathway is not a critical target of MCV T
antigens [37]. Future studies are warranted to elucidate the
molecular mechanisms for AKT pathway activation in MCC.
Since activation of the PI3K/AKT signaling pathway repre-
sents one of the most frequent events in human cancer, specific
inhibitors of PI3K, AKT and additional components of the PI3K/
AKT signaling pathway are currently tested in preclinical and
clinical trials [8]. Notably, MCC showed a significantly higher
AKT phosphorylation than malignant melanoma in our study. In
melanoma, phosphorylation of AKT and activation of the PI3K/
AKT signaling pathway is a well known feature. A previous study
identified AKT phosphorylation in 66% of melanoma samples
[18], congruent with the results observed in this study.
Consequently, inhibition of the PI3K/AKT pathway by specific
Table 2. Response of Merkel cell carcinoma and melanoma cell lines to LY-294002.
doubling time (days) IC 50LY-294002 [mM] cells in S-phase [%] sub-G1 cells [%]
24 hours 48 hours 72 hours control LY-294002 control LY-294002
WaGa* 3 32,5 23,1 12,0 6,8 4,8 4,5 31,1
MKL-1* 3 38,3 27,6 18,4 9,4 5,8 2,1 4,8
MKL-2* 4 64,3 26,1 30,1 9,3 3,9 19,5 27,8
MCC13 1 74,3 41,6 30,7 12,5 10,3 1 4,3
UISO 2 43,0 16,8 14,4 14,7 8 5,2 8,8
BLM 1 57,2 38,8 13,8 11 5,8 1,7 2,9
Skmel28 1 70,9 45,7 26,4 15,1 3,6 0,6 1,3
Doubling times were roughly estimated from the necessary split ratios during culture. IC50 values for the inhibition by LY-294002 were calculated from the MTS assay
date depicted in Figure 4 assuming an exponential relation. The percentage of S-phase and sub-G1 cells were estimated by flow cytometry analysis of propidium iodide
stained cells following 40 hours in the presence of 25 mM LY-294002.
*MCV positive cell lines.
doi:10.1371/journal.pone.0031255.t002
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PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e31255inhibitors has evolved as a promising treatment strategy for
malignant melanoma [24,25]. In our study, MCC cells showing
strong activation of the PI3K/AKT pathway were sensitive to the
PI3K inhibitor LY-294002 in vitro although we cannot exclude that
off target effects may contribute to the observed inhibition.
Since metastasized MCC is a very aggressive tumor with poor
prognosis and very limited therapeutic options, the presented
observations are opening the avenue for targeting the activated
PI3K/AKT pathway as an interesting new option for patients
suffering from advanced MCC.
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